Phase I analysis of hidden operating status for wind turbine

Data-driven methods based on Supervisory Control and Data Acquisition (SCADA) become a recent trend for wind turbine condition monitoring. However, SCADA data are known to be of low quality due to low sampling frequency and complex turbine working dynamics. In this work, we focus on the phase I analysis of SCADA data to better understand turbines' operating status. As one of the most important characterization, the power curve is used as a benchmark to represent normal performance. A powerful distribution-free control chart is applied after the power generation is adjusted by an accurate power curve model, which explicitly takes into account the known factors that can affect turbines' performance. Informative out-of-control segments have been revealed in real field case studies. This phase I analysis can help improve wind turbine's monitoring, reliability, and maintenance for a smarter wind energy system

Interferense of Host Innate Immune Response by Hepatitis E Virus

The host antiviral innate immunity mainly relies on host pattern recognition receptors (PRR) and downstream interferon (IFN) signaling. Host PRR for RNA viruses include Toll-like receptors (TLR) and Retinoic acid-inducible gene I (RIG-I) like receptors (RLR). Activation of both TLR and RLR pathways can eventually lead to the secretion of type I IFNs, which can modulate both innate and adaptive immune responses against viral pathogens, including hepatitis E virus (HEV). HEV causes acute hepatitis in humans and has been responsible for several outbreaks of hepatitis across the world. Currently, no commercial vaccine is available for the prevention of HEV infection in any country except China. HEV biology and pathogenesis as well as its responses to host innate immunity are poorly understood, though other hepatitis viruses, including the hepatitis A, B and C viruses, have been much better studied. In this study, how HEV interferes with IFN induction and IFN-activated signaling had been examined. Results showed that the protein encoded by HEV ORF1 can inhibit type I IFN synthesis and downstream JAK/STAT signaling pathway. However, the HEV ORF3 product is able to enhance RIG-I-mediated signaling to a certain extent. These data suggest that HEV proteins interfere with the host innate immune response and may exert the diverse roles depending on the stage and/or context of infection. These studies contribute to a better understanding of HEV pathogenesis and may facilitate a strategy development for the prevention and control of HEV infection

Multiple epigenetic modification profiles reveal the tumor immune microenvironment and clinical outcomes of uveal melanoma

Uveal melanoma (UM) is an aggressive intraocular cancer that, in 50% of cases, spreads to the patient’s other systems. The exact cause of the increased metastatic rate is still unknown. Methylation and immune response, metastasis, and the expansion of cancer cells are closely related. Additionally, proteins linked to RNA methylation have come to light as possible cancer treatment targets. However, the relationship between methylation-related genes (MRGs) and the tumor microenvironment (TME) is still not understood. The goal of this work was to discover important MRGs and create a signature for UM patients’ prognosis prediction. Using two different data sets, we examined the MRG expression patterns in the transcriptional and genomic regions of 106 UM samples. We discovered a connection between the clinicopathological traits of the patients, their prognosis, the capability of TME cells to infiltrate, and various MRG changes. Following that, we developed an MRGs signature to forecast prognosis, and we evaluated the model’s precision in patients with UM. We grouped the patients into multiple categories based on their clinical traits, looked at the survival rates for various groups within various groupings, and tested their accuracy. Additionally, to increase the practical usability of the MRGs model, we created a very accurate nomogram. TIDE scores were higher in the low-risk group. We go over how MGRs could impact UM’s TME, immunotherapy responsiveness, prognosis, and clinically significant features. We looked for different chemotherapeutic drugs and cutting-edge targeted agents for patients in diverse subgroups in order to better understand MRGs in UM. This helped in the creation of customized therapy to open new doors. We could also further research the prognosis and develop more efficient immunotherapy regimens

A Role for Cardiac Glycosides in GBM Therapy

There is a pressing need for new effective therapeutic strategies to treat glioblastoma (GBM). Cardiac glycoside compounds consisting of both cardenolides and bufadienolides have been shown to possess potent activity against GBM cell lines and in vivo GBM tumors. In addition, recent research has shown that certain cardiac glycoside compounds contribute to an additive and even synergistic manner with the standard of care GBM treatments such as radiotherapy and chemotherapy. Finally, the finding that cardiac glycosides may offer a unique role in the control of GBM stem cells offers hope for better therapeutic outcomes in treating this deadly form of brain cancer

Inhibition of Hepatitis E Virus Replication by Peptide-Conjugated Morpholino Oligomers

Hepatitis E virus (HEV) infection is a cause of hepatitis in humans worldwide. Recently, persistent and chronic HEV infections have been recognized as a serious clinical problem, especially in immunocompromised individuals. To date, there are no FDA-approved HEV-specific antiviral drugs. In this study, we designed and evaluated antisense peptide-conjugated morpholino oligomers (PPMO) as potential HEV-specific antiviral compounds. Two genetically-distinct strains of human HEV, genotype 1 Sar55 and genotype 3 Kernow C1, which cause acute and chronic hepatitis, respectively, were used to evaluate PPMO inhibition of viral replication in liver cells. Four anti-HEV PPMOs tested led to a significant reduction in the levels of viral RNA and HEV capsid protein as well as luciferase yield from Sar55 replicons in S10-3 liver cells, indicating an effective inhibition of HEV replication. PPMO HP1, which targets the ORF1 translation initiation region, was also effective against the genotype 3 Kernow C1 strain in stably-infected HepG2/C3A liver cells. The antiviral activity observed was specific, dose-responsive, potent and effective, suggesting that further exploration of HP1 as a potential HEV-specific antiviral agent is warranted